跳至主要内容

Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy

 On March 18, Medicilon Inc. (Medicilon) and Innoforce Pharmaceuticals (Innoforce) reached a strategic collaboration, focusing on cutting-edge fields such as RNA, cell and gene therapy, and work together to open a new chapter in innovative drug research and development.

Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy.webp

Two-way development, move forward together
Improve the efficiency of RNA, cell and genetic drug research and development

In the exploration of the field of biopharmaceutical, RNA, cell and gene therapy are gradually becoming emerging forces leading the development of the industry with their unique advantages and potential.  These cutting-edge therapies not only open up new path for disease treatment, but also provide new opportunities for biopharmaceutical companies.

As a CRO deeply involved in the field of biopharmaceutical preclinical R&D, Medicilon keeps up with the trends and involved in cutting-edge fields such as bi/multi-specific antibodies, ADCs, mRNA vaccines, small nucleic acid drugs, PROTAC, and CGT.  Medicilon has helped 421 INDs pass the approval of China's NMPA, the US FDA, the EU's EMA and the Australian TGA to enter clinical trials.

Innoforce is a global biopharmaceutical contract development and manufacturing organizations (CDMO) serving domestic and foreign clients.  Focusing on areas such as RNA and cell therapy products, Innoforce is committed to providing one-stop CDMO solutions including plasmids, viral vectors, cell therapy products, RNA and LNP to advanced therapy drug partners.

Dedicated to empowering the cutting-edge areas of drug research and development, Medicilon and Innoforce have reached a strategic collaboration based on the same vision and complementary technical advantages.  According to the strategic collaboration agreement, the two parties will conduct all-round strategic collaboration in business collaboration, resource sharing, global promotion, joint development and commercial licensing.  This collaboration not only achieves the complementary advantages and efficient integration of the resources of both parties, but also demonstrates profound insights and firm confidence in the fields of advanced therapies such as RNA, cell and gene therapy, and will also lead the entire biopharmaceutical industry towards higher and further goals.

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...
发表评论
阅读全文